EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer

Hongyi Lin, Shuncang Zhu, Yinhao Chen, Jinpeng Lu, Chengke Xie, Chengyu Liao, Xiaoxiao Huang, Ge Li, Yongding Wu, Zhiyuan Li, Jianfei Hu, Xinquan Lin und 4 weitere

Drug Resistance Updates · 2025-07 · 81 · 101240

DOI: 10.1016/j.drup.2025.101240 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Resistance Updates, 2025-07. Verfasst von Hongyi Lin und 15 weiteren Autor:innen. Beteiligte Einrichtung: Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, China; Department of Hepatobiliary Pancreatic Surgery, Fuzhou Universit…. Hauptthemen laut MEDLINE: Ferroptosis, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Immunotherapy. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 52 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Fujian Provincial Health Commission, National Natural Science Foundation of China, Fujian Provincial Finance Department.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

AIMS: Current therapeutic strategies for pancreatic ductal adenocarcinoma (PDAC) have limited efficacy in increasing patient survival rates, largely due to ferroptosis resistance and immunosuppression. The aim of this study is to identify molecular mechanisms associated with ferroptosis resistance and immunosuppression in PDAC tumour cells. METHODS: Circular RNA sequencing (circRNA-seq) was performed on clinical samples to identify potential circRNAs that mediate ferroptosis resistance. C11-BODIPY staining, FerroOrange staining, the glutathione ratio, malondialdehyde quantification, and transmission electron microscopy were employed to assess ferroptosis. RNA pulldown, mass spectrometry, RNA immunoprecipitation, and coimmunoprecipitation assays were conducted to investigate the molecular mechanisms involved. A HuNSG mouse xenograft tumour model was utilized to validate therapeutic agents. RESULTS: A circRNA derived from TRIP12 (cTRIP12) was identified in PDAC samples resistant to ferroptosis. cTRIP12 knockdown increased the sensitivity of PDAC cells to ferroptosis and immunotherapy. Subsequent mechanistic studies revealed that cTRIP12 specifically binds to the O-linked N-acetylglucosamine transferase (OGT) protein and increases intracellular O-GlcNAcylation levels, leading to increased protein levels of ferritin heavy chain (FTH) and PD-L1 in tumour cells. Notably, high cTRIP12 expression suppressed ferroptosis sensitivity and increased immune resistance in PDAC cells by functioning as a protein scaffold through its interaction with OGT and protein kinase R-like endoplasmic reticulum kinase (PERK). cTRIP12 inhibition induced ferroptosis in PDAC cells by reducing FTH and PD-L1 expression and synergistically increased the immunotherapy efficacy. In vivo animal experiments confirmed that the triple therapy consisting of GSK2656157, erastin, and anti-CTLA-4 effectively suppressed the progression of PDAC in tumours with high cTRIP12 expression. CONCLUSION: We elucidated the molecular mechanisms underlying the simultaneous occurrence of ferroptosis resistance and immune suppression in PDAC patients. Our study provides a novel therapeutic strategy that could promote ferroptosis in tumour cells and increase immunotherapy efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

FerroptosisPancreatic NeoplasmsCarcinoma, Pancreatic DuctalImmunotherapyHumansAnimalsMiceDrug Resistance, NeoplasmCell Line, TumorRNA, CircularXenograft Model Antitumor AssaysN-Acetylglucosaminyltransferases

Stichwörter der Autor:innen

Circular RNAFerroptosisImmunotherapyO-GlcNAcylationPancreatic ductal adenocarcinoma

Substanzen

RNA, CircularN-Acetylglucosaminyltransferases

Autor:innen und Institutionen

  • Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, China; Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fuzhou 3…
  • Department of Hepatobiliary Surgery, Fujian Institute of Hepatobiliary Surgery, Fujian Medical University Union Hospital, Fuzhou 350001, China.
  • Department of Hepatobiliary Pancreatic Surgery, Fuzhou University Affiliated Provincial Hospital, Fujian Provincial Hospital, Fuzhou 350001, China.
  • Fuzhou University, Fuzhou 350001, China.
  • Shengli Clinical Medical College of Fujian Medical University, Fuzhou 350001, China; Fuzhou University, Fuzhou 350001, China; Fujian Provincial Institute of Clinical Geriatrics, Fuzhou 350001, China; Fujian Key Laborato…

Förderung

  • Fujian Provincial Health Commission
  • National Natural Science Foundation of China
  • Fujian Provincial Finance Department

Zitieren

APA

Lin, H., Zhu, S., Chen, Y., Lu, J., Xie, C., Liao, C., Huang, X., Li, G., Wu, Y., Li, Z., Hu, J., Lin, X., Tian, Y., Li, Q., Wang, Z., & Chen, S. (2025). Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer. Drug Resistance Updates, 81, 101240. https://doi.org/10.1016/j.drup.2025.101240

Vancouver

Lin H, Zhu S, Chen Y, Lu J, Xie C, Liao C, et al. Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer. Drug Resistance Updates. 2025;81:101240. doi:10.1016/j.drup.2025.101240

BibTeX
@article{Lin2025,
  author = {Lin, Hongyi and Zhu, Shuncang and Chen, Yinhao and Lu, Jinpeng and Xie, Chengke and Liao, Chengyu and Huang, Xiaoxiao and Li, Ge and Wu, Yongding and Li, Zhiyuan and Hu, Jianfei and Lin, Xinquan and Tian, Yifeng and Li, Qiaowei and Wang, Zuwei and Chen, Shi},
  title = {Targeting cTRIP12 counteracts ferroptosis resistance and augments sensitivity to immunotherapy in pancreatic cancer},
  journal = {Drug Resistance Updates},
  year = {2025},
  volume = {81},
  pages = {101240},
  doi = {10.1016/j.drup.2025.101240}
}
Kostenlos starten →